04:39 PM EDT, 03/28/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said late Thursday an initial analysis of data showed that the first of two induction studies in a phase 3 trial of Zeposia in adults with Crohn's disease didn't meet the primary endpoint of clinical remission at week 12.

The company said it plans to finalize a full assessment of the data and will later release the results.

Separately, Bristol-Myers Squibb ( BMY ) said that a phase 3 trial assessing Krazati to treat people with non-small cell lung cancer with a KRASG12C mutation met the primary endpoint of progression-free survival.

The trial also reached the secondary endpoint of overall response rate, the company said.

The study is ongoing to evaluate an additional secondary endpoint of overall survival, it said.

Price: 53.93, Change: -0.3, Percent Change: -0.55